Selenium in the Treatment of Complicated Lymphatic Malformations

Inclusion Criteria

• •Patients must have clinical and radiographic features consistent with a lymphatic malformation (LM). Patients with combined venous lymphatic malformations (CVLM) will be included if the predominant componet is lymphatic based on MRI. Both macrocystic and microcystic LM will be eligible. Tissue biopsy is required to confirm the presence of an abnormal lymphatic malformation.
• •All patients diagnosed with lymphatic malformations between 14 and 30 years of age will be eligible.
• •Patients must have lymphatic malformations with potential to cause morbidity including one or more of the following: Lymphedema, Coagulopathy, Chronic Pain, Recurrent Cellulitis (\> 1 episodes/year), Ulceration and/or bleeding, Impairment of organ function, Visceral and/or bone involvement, or Disfigurement.
• •All patients and/or their parents or legal guardians must sign a written informed consent. All institutional FDA requirements for human studies must be met.